Drug Trial Radar · NCT07082543
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis
Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Jun 30, 2025
Primary completion
Feb 6, 2028
Study completion Mar 6, 2028
Sponsor
- Lead sponsor
- Azafaros B.V.Industry
- Sponsor type
- Industry
- First posted
- Jul 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 4 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of GM1 gangliosidosis or GM2 gangliosidosis
Conditions
- Gangliosidoses, GM2
- Gangliosidosis, GM1
Interventions
AZ-3102Drug
Nizubaglustat
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in total Scale for the Assessment and Rating of Ataxia (SARA) scoreTime frame: Baseline to month 18
- Change from baseline in functional SARA scoreTime frame: Baseline to month 18
Locations
27 sites in 14 countries. Site status is shown where the registry gives one.
UCSF Children's Hospital and Research Center at Oakland
Oakland, California
University of Minnesota Medical School
Minneapolis, Minnesota
Mayo Clinic Children's Center - PIN
Rochester, Minnesota
Children's Medical Center Dallas
Dallas, Texas
Lysosomal Rare Disorders Research and Treatment Center
Fairfax, Virginia
Hospital Universitario Austral
Ciudad Autónoma Buenos Aires, Buenos Aires, Argentina
Hospital de Niños de La Santisima Trinidad
Córdoba, Córdoba Province, Argentina
Women's and Children's Hospital
North Adelaide, South Australia, Australia
Instituto Fernandes Figueira
Rio de Janeiro, Rio de Janeiro, Brazil
Hospital de Clinicas de Porto Alegre (HCPA) - PPDS
Porto Alegre, Rio Grande do Sul, Brazil
M.A.G.I.C. Clinic Ltd. Metabolics and Genetics in Calgary
Calgary, Alberta, Canada
AP-HP - Hôpital Armand Trousseau
Paris, France
AP-HP - Hôpital de la Pitié Salpétrière
Paris, France
SphinCS GmbH
Höchheim, Germany
Amrita Institute of Medical Sciences and Research Centre
Ernākulam, Kerala, India
All India Institute of Medical Sciences (AIIMS) - New Delhi
New Delhi, National Capital Territory of Delhi, India
JK Lone Hospital
Jaipur, Rajasthan, India
Fondazione IRCCS Istituto Neurologico Carlo Besta
Milan, Italy
ULS de Santa Maria,EPE - Hospital de Santa Maria - PPDS
Lisbon, Portugal
ULS de Santo António, EPE - Centro Materno Infantil Norte
Porto, Porto District, Portugal
Hospital Universitario Vall d'Hebron - PPDS
Barcelona, Barcelona, Spain
Hospital Infantil Universitario Niño Jesus - PIN
Madrid, Madrid, Spain
Sahlgrenska universitetssjukhuset Östra
Gothenburg, Västra Götaland County, Sweden
Inselspital - Universitätsspital Bern
Bern, Canton of Bern, Switzerland
Balcali Hastanesi Saglik Uygulama ve Arastirma Merkezi
Adana, Adana, Turkey (Türkiye)
Gazi Universitesi Saglik Arastirma ve Uygulama Merkezi
Çankaya, Ankara, Turkey (Türkiye)
Ege Universitesi Tip Fakultesi
Bornova, İzmir, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.